Gene therapy hope for SMA kids: early trial launches
NCT ID NCT07617779
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new gene therapy called NKG001 in 21 children under 5 with spinal muscular atrophy (SMA). The therapy is given as a single dose, either through a vein or combined with a spinal injection. The main goal is to check safety and find the best dose, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NKG001 (a gene therapy)
- What this could lead to
- If successful, this could point toward a treatment that slows or stops the progression of spinal muscular atrophy in young children.
- What could go wrong
- This is a very early, small trial (21 participants) focused on safety, not proof of effectiveness. The therapy may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY (SMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New knee device may help kids with SMA build leg strength
- New VR device aims to make exercise fun for kids with muscle weakness
- Wearable tech monitors SMA babies at home to pinpoint best time for extra treatment
- Summer camp aims to boost strength in kids with SMA
- Can a support group boost confidence for parents of kids with DMD or SMA?
- Zolgensma's long-term effects under the microscope in new 5-year study